PDS Biotechnology Corporation (PDSB)
PDSB trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | PDSB on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2015 |
| SEC CIK | 0001472091 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "As a result of these uncertainties, the Company has concluded that substantial doubt exists about the Company's ability to continue as a going concern for a period of at least 12 months from the date of the issuance of these unaudited Condensed Consolidated Financial Statements." | 10-Q 2026-08-13 |
| Cash and burn | $5.6M cash; operating cash flow -$4.2M a quarter. | Report 2026-06-30 |
| Shares outstanding | 55,971,338 (2026-08-06); 46,633,362 a year earlier; 30,868,188 three years earlier. | Cover page 2026-08-06 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-06-15 |
| Exchange deficiency notices, 12 months | 2 (8-K item 3.01) | 8-K 2026-07-31 |
| Auditor | KPMG LLP, Short Hills, New Jersey, United States | PCAOB Form AP 2026-04-30 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
| Market cap check | The listing's market cap implies 122,704,544 shares at the 2026-11-13 price; the latest SEC cover count is 55,971,338 as of 2026-08-06. One of the two share counts is stale. | Nasdaq screener and SEC cover page |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$9.8M | -$2.8M | $5.6M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | Not filed | -$7.3M | -$4.4M | $21.7M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q4 2025 2025-12-31 | Not filed | -$7.6M | -$3.7M | $26.7M | No debt tags | Needs four quarters | 10-K 2026-03-30 |
| Q3 2025 2025-09-30 | Not filed | -$9.0M | -$5.9M | $26.2M | No debt tags | Needs four quarters | 10-K 2026-03-30 |
| Q2 2025 2025-06-30 | Not filed | -$9.4M | -$9.1M | $31.9M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | Not filed | -$8.5M | -$9.0M | $40.0M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q4 2024 2024-12-31 | Not filed | -$8.0M | -$8.2M | $41.7M | No debt tags | Needs four quarters | 10-K 2026-03-30 |
| Q3 2024 2024-09-30 | Not filed | -$10.7M | -$8.0M | $49.8M | No debt tags | Needs four quarters | 10-K 2026-03-30 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-10-14 |
| Latest annual report | 10-K/A | 2026-04-28 |
| Latest quarterly / interim | 10-Q | 2026-11-16 |
| Latest current report | 8-K | 2026-11-13 |
| Latest proxy | DEFA14A | 2026-06-26 |
Source: SEC EDGAR submissions feed, 799 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -29.0% |
| 1 month | -45.4% |
| 3 months | +274.7% |
| Year to date | +13.4% |
| 1 year | +3.3% |
| From 52-week high | -45.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IMUX | Immunic Inc. | $7.23 | -3.86% | $114.8M |
| CATX | Perspective Therapeutics Inc. | $0.9238 | -2.05% | $111.6M |
| OKUR | OnKure Therapeutics Inc. | $2.75 | +4.56% | $111.4M |
| NERV | Minerva Neurosciences Inc | $2.20 | -4.35% | $109.6M |
| UPB | Upstream Bio Inc. | $2.15 | -22.66% | $117.8M |
| FHTX | Foghorn Therapeutics Inc. | $1.79 | -13.53% | $107.3M |
| BGM | BGM Group Ltd. | $8.01 | +1.71% | $107.0M |
| SPRB | Spruce Biosciences Inc. | $42.25 | -2.45% | $121.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier